<DOC>
	<DOCNO>NCT03046459</DOCNO>
	<brief_summary>This open-label , single ascend dose study characterize safety PK/PD profile IV BNZ132-1-40 , novel peptide inhibitor multiple cytokine IL-2 family .</brief_summary>
	<brief_title>A First-in-Human Study BNZ132-1-40</brief_title>
	<detailed_description>This open-label study single dose intravenous BNZ132-1-40 administer healthy adult subject . Subjects follow 30 day treatment collection safety , PK PD data . Cohorts 6 subject enrol dose level .</detailed_description>
	<criteria>male nonpregnant , nonlactating female ongoing clinically significant medical condition willing able provide inform consent use Rx OTC medication , oral contraceptive Recent systemic infection Clinicallysignificant abnormal clinical lab , ECG physical examination Immunization 30 day prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cytokine</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>Safety Issues</keyword>
</DOC>